Peer-Reviewed Publication: Longitudinal Dynamics of Polyglutamine-Expanded ATXN3 in Biofluids of Spinocerebellar Ataxia Type 3
As the search for reliable biomarkers in neurodegenerative diseases continues, researchers are working to better understand how disease-related proteins can support diagnosis, monitoring, and future treatment development. A newly published study in Movement Disorders investigates polyglutamine-expanded ATXN3 in Spinocerebellar Ataxia Type 3 (SCA3), one of the most common inherited ataxias.
The study, co-authored by Rana Hanna Al-Shaikh, MD, Senior Medical Monitor at P95 Julius Clinical, contributes to the growing body of evidence supporting biomarker research in rare neurological disorders. The findings offer valuable perspectives for researchers and clinicians working to advance the understanding and management of SCA3.
Related resources
Fact Sheet: Rescue Study Experience
Rescue Study Expertise for At-Risk Clinical Trials When clinical studies face enrollment shortfalls, startup delays, operational challenges, or CRO underperformance, sponsors need more than additional resources. They need an experienced partner c...
Case Study: Maintaining Enrollment Momentum and Data Quality in a Multinational Phase II Alzheimer’s Disease Study
How Strategic Site Engagement and Patient-Centric Retention Supported Study Success A Phase II Alzheimer's disease study evaluating an investigational therapy faced significant operational challenges, including a complex biomarker-driven design r...
Fact Sheet: Parkinson’s Disease Clinical Development
Parkinson’s Disease CRO Expertise for Complex Clinical Trials As Parkinson’s disease research advances toward earlier intervention, disease modification, and prevention-focused approaches, sponsors need a partner with deep therapeutic experti...